XML 82 R67.htm IDEA: XBRL DOCUMENT
v3.22.0.1

ACQUISITIONS AND OTHER ARRANGEMENTS - Celerity Pharmaceuticals, LLC Narrative (Details) - USD ($) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Acquisitions And Collaborations [Line Items] |  |  |  |
Loss on acquisition |  | $ (962,000,000) | $ (635,000,000) |
Celerity Pharmaceutical LLC |  |  |  |
Acquisitions And Collaborations [Line Items] |  |  |  |
Payment to acquire the rights |  |  |  | $ 86,000,000
Maximum contingent future payments |  | $ 77,000,000 |  |
Celerity Pharmaceutical LLC | Developed Technology Rights |  |  |  |
Acquisitions And Collaborations [Line Items] |  |  |  |
Estimated useful lives |  | 12 years |  |
Celerity Pharmaceutical LLC | Minimum |  |  |  |
Acquisitions And Collaborations [Line Items] |  |  |  |
Loss on acquisition | $ 30,000,000 |  |  |
Celerity Pharmaceutical LLC | Maximum |  |  |  |
Acquisitions And Collaborations [Line Items] |  |  |  |
Loss on acquisition | $ 60,000,000 |  |  |

X
- Definition Acquisitions and collaborations. + References No definition available. + Details
Name: | bax_AcquisitionsAndCollaborationsLineItems
Namespace Prefix: | bax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bax_CelerityPharmaceuticalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |